DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release

Brain Research

Volumn 907, Issue 1-2, 2001, Pages 151-155

  Ichikawa, Junji ^a,b   Dai, Jin ^a,b   Meltzer, Herbert Y ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

5 HT1A receptor; 5 HT2A receptor; Clozapine; Cortical dopamine release; DOI; Mircodialysis

Indexed keywords

2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLOZAPINE; DOPAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A AGONIST; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; DIMETHOXY 4 INDOPHENYL 2 AMINOPROPANE; DIMETHOXY-4-INDOPHENYL-2-AMINOPROPANE; DRUG DERIVATIVE; FLUOROBENZENE; INDOPHENOL; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 1 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; DRUG RECEPTOR BINDING; NEUROTRANSMITTER RELEASE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; ANIMAL; CHEMICAL PHENOMENA; DRUG ANTAGONISM; MICRODIALYSIS; SECRETION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DEPRESSION, CHEMICAL; DOPAMINE; FLUOROBENZENES; INDOPHENOL; MICRODIALYSIS; PIPERAZINES; PIPERIDINES; PREFRONTAL CORTEX; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SECRETORY RATE; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 0035854283     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(01)02596-3     Document Type: Article

References (29)

1. 2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system
2. Effects of the selective 5-HT receptor agonists 8-OHDPAT and DOI on behavior and brain biogenic amines of rats
3. 2A receptor activation enhances dialysis levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats
4. 2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat
5. 1C receptors
6. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs
7. 1A receptor agonist, potentiated S(-) sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum
8. 1A receptors on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens
9. 1A receptor activation: A possible mechanism of atypical antipsychotic-induced cortical dopamine release
10. M100907, a 5HT2A antagonist, potentiates the ability of R(+)-8-OH-DPAT to increase extracellular dopamine (DA-ext) levels in rat medial prefrontal cortex (mPFC)
11. Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens
12. 2A/2C receptor agonist and antagonist on phencyclidine-induced dopamine release in rat medial prefrontal cortex
13. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
14. 2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner
15. i values
16. The role of serotonin in antipsychotic drug action
17. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
18. 1C/2 antagonists as therapeutic agents
19. 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo
20. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study
21. 2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex
22. 2C) receptor antagonist properties of compounds
23. 1C receptors
24. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
25. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens
26. 2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats
27. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex
28. 5-Hydroxytryptamine receptors